- Home
- NAUT
as 07-26-2024 4:00pm EST
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
Upcoming Earnings Alert:
Get ready for potential market movements as Nautilus Biotechnolgy Inc. NAUT prepares to release earnings report on 30 Jul 2024.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 337.0M | IPO Year: | N/A |
| Target Price: | $5.00 | AVG Volume (30 days): | 72.4K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.19 - $4.00 | Next Earning Date: | 07-30-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 8016.30% |
Stock Insider Trading Activity of Nautilus Biotechnolgy Inc. (NAUT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Sujal M | NAUT | CEO, President, and Secretary | Mar 8 '24 | Buy | $2.84 | 12,044 | $34,215.80 | 10,064,488 | SEC Form 4 |
| Patel Sujal M | NAUT | CEO, President, and Secretary | Mar 8 '24 | Buy | $2.99 | 2,430 | $7,262.06 | 10,052,444 | SEC Form 4 |
| Patel Sujal M | NAUT | CEO, President, and Secretary | Mar 5 '24 | Buy | $2.65 | 7,405 | $19,596.59 | 10,021,893 | SEC Form 4 |
| Patel Sujal M | NAUT | CEO, President, and Secretary | Mar 5 '24 | Buy | $2.70 | 9,267 | $25,033.87 | 10,031,160 | SEC Form 4 |
| Patel Sujal M | NAUT | CEO, President, and Secretary | Mar 5 '24 | Buy | $2.89 | 18,854 | $54,423.96 | 10,050,014 | SEC Form 4 |
Latest Nautilus Biotechnolgy Inc. News
NAUT Breaking Stock News: Dive into NAUT Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024
Simply Wall St.
24 days ago
With 32% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's future
GlobeNewswire
2 months ago
Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Simply Wall St.
3 months ago
We're Hopeful That Nautilus Biotechnology (NASDAQ:NAUT) Will Use Its Cash Wisely
GuruFocus.com
3 months ago
Nautilus Biotechnology Inc (NAUT) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...
GlobeNewswire
3 months ago
Nautilus Biotechnology Reports First Quarter 2024 Financial Results
GuruFocus.com
3 months ago
Nautilus Biotechnology Inc (NAUT) Q1 2024 Earnings: Narrower Loss Than Expected
GlobeNewswire
4 months ago
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
Compare NAUT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NAUT Nautilus Biotechnolgy Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.